Back to search

Peptide record

TPDB15806

Antibacterial Toxicity modified_plain modified
10 source-reported length (unverified)
Basic Information
TPDB15806
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
dbAMP Peptipedia
modified_plain
Yes
A modified multi-activity (Antibacterial and Toxicity) peptide record curated from dbAMP and Peptipedia, without an available 3D structural model. Source-reported length: 10 (unverified).
Modified, details unspecified
Sequence
ALWKKLLKKX

Source notation is retained verbatim; residue notation and chemical identity have not been independently validated. The displayed length is source-reported and unverified.

Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
10 source-reported length (unverified)
Evidence Records 7 records
Evidence 1 Activity

Activity

8% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
8% Hemolysis | 64 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients. | Biomolecules | 2019
Evidence 2 Activity

Activity

18% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
18% Hemolysis | 128 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients. | Biomolecules | 2019
Evidence 3 Activity

Activity

35% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
35% Hemolysis | 256 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients. | Biomolecules | 2019
Evidence 4 Activity

Activity

90% Hemolysis
Toxicity
512 µM
Hemolytic Cytotoxic
90% Hemolysis | 512 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020
Evidence 5 Activity

Activity

57% Killing
Toxicity
8 µM
Cytotoxic
57% Killing | 8 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020
Evidence 6 Activity

Activity

95% Killing
Toxicity
32-64 µM
Cytotoxic
95% Killing | 32-64 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020
Evidence 7 Activity

Activity

98% Killing
Toxicity
128 µM
Cytotoxic
98% Killing | 128 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020